Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK

• Published in: Annals of oncology Vol. 21; no. 7; pp. 1529 - 1536
• Main Authors: Logman, J.F.S., Heeg, B.M.S., Botteman, M.F., Kaura, S., van Hout, B.A.
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 01.07.2010; Oxford University Press
• Subjects: Aged; Aged, 80 and over; AIBL; Antineoplastic agents; aromatase inhibitor; Aromatase Inhibitors - adverse effects; Biological and medical sciences; Bone Density - drug effects; Bone Density Conservation Agents - therapeutic use; bone loss; breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - economics; Breast Neoplasms - pathology; Cohort Studies; Cost-Benefit Analysis; cost-effectiveness; Diphosphonates - therapeutic use; Diseases of the osteoarticular system; Female; Gynecology. Andrology. Obstetrics; Humans; Imidazoles - therapeutic use; Letrozole; Mammary gland diseases; Markov Chains; Medical sciences; Middle Aged; Neoplasm Staging; Nitriles - adverse effects; Osteoporosis, Postmenopausal - economics; Osteoporosis, Postmenopausal - prevention & control; Osteoporosis. Osteomalacia. Paget disease; Pharmacology. Drug treatments; Quality-Adjusted Life Years; Salvage Therapy; Survival Rate; Treatment Outcome; Triazoles - adverse effects; Tumors; Zoledronic Acid; United Kingdom; Europe; cost-effectiveness; breast cancer; AIBL; zoledronic acid; bone loss; aromatase inhibitor; Antineoplastic agent; Antiosteoporotic; Breast disease; Menopause; Diseases of the osteoarticular system; Antiresorptive agent; Diphosphonic acid derivatives; Early stage; Fracture; Bisphosphonates; Prevention; Osteoporosis; Zoledronic acid; Postmenopause; Adult; Female; Bone defect; Woman; Osteopenia; Public health; Cost efficiency analysis; Human; Aromatase inhibitor; Breast cancer; Malignant tumor; Trauma; Mammary gland diseases; Health economy; Cancer

Aromatase inhibitors are used as adjuvant therapy for breast cancer (BC) and are associated with accelerated bone loss. Zoledronic acid (ZOL) prevents aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with BC. This analysis assessed the cost-effectiveness of ZOL for prevention...